AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 22 min read$DH

Definitive Healthcare Corp. (DH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Definitive Healthcare Appoints Clay Ritchey as CEO Mr. Ritchey brings more than 25 years of deep healthcare expertise to Definitive Framingham, MA (September 2, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthca

Original reporting
SEC EDGAR 8-K
Published Sep 2, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$DH
Neutral
medium confidence
Mentioned
$DH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DHNeutralMed
01

Why it matters

The CEO change is a primary corporate action that could affect strategic execution and stock valuation.

02

Market read

Executive transition is a material corporate event for investors tracking healthcare data providers.

03

What to watch

Potential integration challenges with recent acquisitions and the competitive AI landscape.

Relevance 6/10Novelty 7/10Timing: effective September 8, 2026

Background

Definitive Healthcare provides market data and analytics for the healthcare industry and is listed on Nasdaq.

Company-level read

Ticker impact

$DHNeutralMedium confidence
Context

Definitive Healthcare filed an 8‑K announcing the appointment of Clay Ritchey as CEO effective September 8, 2026.

Expected impact

Potential modest upside if market views the new CEO favorably; downside risk if transition raises execution concerns.

Evidence & confidence

CEO changes are material but the impact depends on execution track record; no immediate financial metrics disclosed.

Market effects

Sector

May signal continued consolidation in healthcare data and analytics sector.

Regional

Limited to U.S. listed healthcare information providers.

Global

Low; primarily affects niche market participants.

Counterpoint

What could challenge this read

New CEO could struggle to deliver AI initiatives, leading to underperformance.

Key entities

  • person
    Clay Ritchey

    Newly appointed CEO of Definitive Healthcare.

  • person
    Kevin Coop

    Outgoing CEO of Definitive Healthcare.

Read at source← All news

Related articles

SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 3
$DHMedAI 8/10

Advent Proposed $1.02 Cash Take-Private of Definitive Healthcare:

Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.

hedgeco.net1 min
SEP 2
$DHHigh

Definitive Healthcare stock surges 13% on Advent buyout offer

Definitive Healthcare (NASDAQ:DH) shares rose 13% after Advent International offered to buy the company for $1.02 per share, a 36% premium over its 60-day average. The deal requires approval from a special committee and Jason Krantz's stock rollover. Definitive Healthcare also appointed Clay Ritchey as CEO, replacing Kevin Coop.

investing.com2 min
AUG 18
$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

fool.com6 min
AUG 10
$DHHigh

Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

SEC EDGAR 8-K6 min